A comparison of treatment response to biologics in asthma-COPD overlap and pure asthma: Findings from the PRISM study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shim, Ji-Su | - |
dc.contributor.author | Kim, Hyunkyoung | - |
dc.contributor.author | Kwon, Jae-Woo | - |
dc.contributor.author | Park, So-Young | - |
dc.contributor.author | Kim, Sujeong | - |
dc.contributor.author | Kim, Byung-Keun | - |
dc.contributor.author | Nam, Young-Hee | - |
dc.contributor.author | Yang, Min-Suk | - |
dc.contributor.author | Kim, Mi-Yeong | - |
dc.contributor.author | Kim, Sae-Hoon | - |
dc.contributor.author | Lee, Byung-Jae | - |
dc.contributor.author | Lee, Taehoon | - |
dc.contributor.author | Kim, Sang-Ha | - |
dc.contributor.author | Park, So Young | - |
dc.contributor.author | Cho, Young-Joo | - |
dc.contributor.author | Park, Chan Sun | - |
dc.contributor.author | Jung, Jae-Woo | - |
dc.contributor.author | Park, Han-Ki | - |
dc.contributor.author | Kim, Joo-Hee | - |
dc.contributor.author | Choi, Jeong-Hee | - |
dc.contributor.author | Moon, Ji-Yong | - |
dc.contributor.author | Adcock, Ian | - |
dc.contributor.author | Chung, Kian Fan | - |
dc.contributor.author | Kim, Min-Hye | - |
dc.contributor.author | Kim, Tae-Bum | - |
dc.date.accessioned | 2024-01-19T05:30:41Z | - |
dc.date.available | 2024-01-19T05:30:41Z | - |
dc.date.issued | 2023-12 | - |
dc.identifier.issn | 1939-4551 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/71189 | - |
dc.description.abstract | Background: Despite the increasing use of biologics in severe asthma, there is limited research on their use in asthma-chronic obstructive pulmonary disease overlap (ACO). We compared real-world treatment responses to biologics in ACO and asthma. Methods: We conducted a multicenter, retrospective, cohort study using data from the Precision Medicine Intervention in Severe Asthma (PRISM). ACO was defined as post-bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) <0.7 and a smoking history of >10 pack-years. Physicians selected biologics (omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab) based on each United States Food & Drug Administration (FDA) approval criteria. Results: After six-month treatment with biologics, both patients with ACO (N = 13) and asthma (N = 81) showed positive responses in FEV1 (10.69 ± 17.17 vs. 11.25 ± 12.87 %, P = 0.652), Asthma Control Test score (3.33 ± 5.47 vs. 5.39 ± 5.42, P = 0.290), oral corticosteroid use (−117.50 ± 94.38 vs. −115.06 ± 456.85 mg, P = 0.688), fractional exhaled nitric oxide levels (−18.62 ± 24.68 vs. −14.66 ± 45.35 ppb, P = 0.415), sputum eosinophils (−3.40 ± 10.60 vs. −14.48 ± 24.01 %, P = 0.065), blood eosinophils (−36.47 ± 517.02 vs. −363.22 ± 1294.59, P = 0.013), and exacerbation frequency (−3.07 ± 4.42 vs. −3.19 ± 5.11, P = 0.943). The odds ratio for exacerbation and time-to-first exacerbation showed no significant difference after full adjustments, and subgroup analysis according to biologic type was also showed similar results. Conclusions: Biologics treatment response patterns in patients with ACO and asthma were comparable, suggesting that biologics should be actively considered for ACO patients as well. © 2023 The Author(s) | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier Inc. | - |
dc.title | A comparison of treatment response to biologics in asthma-COPD overlap and pure asthma: Findings from the PRISM study | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.waojou.2023.100848 | - |
dc.identifier.bibliographicCitation | World Allergy Organization Journal, v.16, no.12 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 001137305100001 | - |
dc.identifier.scopusid | 2-s2.0-85179602016 | - |
dc.citation.number | 12 | - |
dc.citation.title | World Allergy Organization Journal | - |
dc.citation.volume | 16 | - |
dc.type.docType | Article | - |
dc.publisher.location | 네델란드 | - |
dc.subject.keywordAuthor | Asthma | - |
dc.subject.keywordAuthor | Asthma-COPD overlap | - |
dc.subject.keywordAuthor | Biologics | - |
dc.subject.keywordAuthor | Monoclonal antibodies | - |
dc.subject.keywordAuthor | Treatment response | - |
dc.subject.keywordPlus | MEPOLIZUMAB | - |
dc.subject.keywordPlus | OBSTRUCTION | - |
dc.subject.keywordPlus | DEFINITION | - |
dc.subject.keywordPlus | OMALIZUMAB | - |
dc.relation.journalResearchArea | Allergy | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Allergy | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.